See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used to treat type 2 diabetes and, in some cases, to help with weight loss [1]. Its mechanism of action includes slowing down gastric emptying, increasing insulin secretion, and reducing appetite [1]. However, there is limited research available on the direct impact of Ozempic on athletic performance.

A study published in the Journal of Clinical Endocrinology & Metabolism investigated the effects of semaglutide on energy metabolism during exercise in individuals with obesity [2]. The results indicated that semaglutide treatment led to increased fat oxidation during exercise, suggesting a potential effect on endurance performance. However, this study did not include athletes or assess the impact on athletic performance directly.

Another study in the Journal of the American College of Cardiology evaluated the effects of semaglutide on cardiovascular risk factors in patients with type 2 diabetes [3]. While the study did not focus on athletic performance, it did find that semaglutide treatment was associated with a decrease in body weight, waist circumference, and systolic blood pressure, which could indirectly influence athletic performance.

In summary, there is limited evidence on the direct impact of Ozempic (semaglutide) on athletic performance. However, it may have potential effects on energy metabolism during exercise and could indirectly influence athletic performance by reducing body weight and cardiovascular risk factors. Further research is needed to determine the specific effects of Ozempic on athletic performance.

Sources:
[1] "Ozempic (semaglutide) injection, for subcutaneous use." DailyMed, U.S. National Library of Medicine, 2021, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6d20e10e-9c3d-46f1-89a6-a19e368d9e6f&type=display.
[2] Martins, C., et al. "Semaglutide increases fat oxidation during exercise in individuals with obesity." The Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 12, 2020, pp. dgaa631-dgaa631.
[3] Marso, S. P., et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine, vol. 375, no. 14, 2016, pp. 1228-1239.
[4] "Semaglutide." DrugPatentWatch, https://www.drugpatentwatch.com/drugs/semaglutide.